CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Pfizer, BioNTech say Covid-19 vaccine safe for younger kids

By Joyanta Acharjee

14:55, 20 September 2021

Photo of a child receiving a vaccination
Vaccinating children Photo: Shutterstock

Drug companies Pfizer and BioNTech said Monday that their Covid-19 vaccine works for children aged 5 to 11.

The trial showed "a favorable safety profile and robust neutralizing antibody responses" in children 5 to 11 years of age using a two-dose regimen of 10 microgrammes administered 21 days apart, the companies said. This is a smaller dose than the 30 microgramme dosage for people aged 12 and above.

At 9:57 am EST Pfizer shares were up 0.77% at $44.23 while its German partner BioNTech was down 3% at $347.20. Shares of Moderna, another vaccine-maker, were down 0.78% at $426.71. 

"These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency," Pfizer Chair and CEO Albert Bourla said in a press release.

AAPL

178.34 Price
-0.100% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 0.06

NVDA

382.93 Price
-0.510% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 0.15

COIN

53.00 Price
+0.460% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 0.15

TSLA

224.07 Price
+0.740% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 0.08

US pediatric Covid-19 cases up 

“Since July, pediatric cases of Covid-19 have risen by about 240% in the US, which underscores the public health need for vaccination,” Pfizer’s Bourla added.

The vaccine made by Pfizer and BioNTech is already available for anyone aged 12 years and above.

Data from the other two age groups in the trial – children aged 2 to 5 years and children aged 6 months to 2 years – are expected as soon as the fourth quarter of 2021.

Read more: Pfizer stock price forecast 2021: don’t count on the vaccine to support stock

Related topics

Rate this article

Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 535.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading